X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   MYLAN
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
MYLAN
Dec-14
ALEMBIC PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6454,285-   
Low Rs4703,019-   
Sales per share (Unadj.) Rs166.11,466.8-  
Earnings per share (Unadj.) Rs21.9176.7-  
Cash flow per share (Unadj.) Rs27.5284.4-  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs117.8729.1-  
Shares outstanding (eoy) m188.52378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.42.5 134.8%   
Avg P/E ratio x25.520.7 123.2%  
P/CF ratio (eoy) x20.312.8 157.9%  
Price / Book Value ratio x4.75.0 94.5%  
Dividend payout %18.30-   
Avg Mkt Cap Rs m105,0901,381,812 7.6%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m6,2280-   
Avg. sales/employee Rs ThNM22,199.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,674.3-  
INCOME DATA
Net Sales Rs m31,308554,991 5.6%  
Other income Rs m70-3,235 -2.2%   
Total revenues Rs m31,378551,756 5.7%   
Gross profit Rs m6,431138,029 4.7%  
Depreciation Rs m1,05540,762 2.6%   
Interest Rs m3423,939 0.1%   
Profit before tax Rs m5,41370,093 7.7%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2042,947 40.8%   
Profit after tax Rs m4,12866,858 6.2%  
Gross profit margin %20.524.9 82.6%  
Effective tax rate %22.24.2 528.8%   
Net profit margin %13.212.0 109.5%  
BALANCE SHEET DATA
Current assets Rs m18,247487,910 3.7%   
Current liabilities Rs m11,235381,448 2.9%   
Net working cap to sales %22.419.2 116.8%  
Current ratio x1.61.3 127.0%  
Inventory Days Days8678 109.6%  
Debtors Days Days61107 57.2%  
Net fixed assets Rs m20,035128,396 15.6%   
Share capital Rs m37719,626 1.9%   
"Free" reserves Rs m21,8240-   
Net worth Rs m22,201275,885 8.0%   
Long term debt Rs m5,000412,145 1.2%   
Total assets Rs m39,4111,111,240 3.5%  
Interest coverage x160.23.9 4,078.3%   
Debt to equity ratio x0.21.5 15.1%  
Sales to assets ratio x0.80.5 159.1%   
Return on assets %10.68.2 129.3%  
Return on equity %18.624.2 76.7%  
Return on capital %19.713.6 144.8%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Net fx Rs m7,6960-   
CASH FLOW
From Operations Rs m3,12472,954 4.3%  
From Investments Rs m-8,844-57,534 15.4%  
From Financial Activity Rs m5,026-19,223 -26.1%  
Net Cashflow Rs m-693-3,803 18.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare ALEMBIC PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ALEMBIC PHARMA With: GSK PHARMA  FRESENIUS KABI ONCO.  AJANTA PHARMA  FDC LTD.  LUPIN LTD  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views On News

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - BIOCON LTD COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS